Research Progress in Liver-Regenerating Microenvironment and DNA Methylation in Hepatocellular Carcinoma: The Role of Traditional Chinese Medicine

Wang, Minggang; Ye, Qianling; Mao, Dewen; Li, Hanmin

doi:10.12659/msm.920310

Cited by 11 publications

(7 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA methylation modifications are extensively involved in regulating physiological and pathological pathways in HCC [ 26 , 27 ]. We explored the DNA methylation status of the SPC25 gene in HCC using MEXPRESS.…”

Section: Resultsmentioning

confidence: 99%

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

Zhang

Zhou

Xie

et al. 2020

Aging

View full text Add to dashboard Cite

Background: The nuclear division cycle 80 (NDC80) complex assures proper chromosome segregation during the cell cycle progression. SPC25 is a crucial component of NDC80, and its role in hepatocellular carcinoma (HCC) has been explored recently. This study characterized the differential expression of SPC25 in HCC patients of different races and HBV infection status. Methods: Expression patterns of SPC25 were evaluated in TCGA and Chinese HCC patients. Kaplan-Meier analysis was applied to examine the predictive value of SPC25. In vitro and in vivo functional assays were conducted to explore the role of SPC25 in HCC. Bioinformatics methods were applied to investigate the regulatory mechanisms of SPC25. Findings: The mRNA levels of SPC25 were up-regulated in HCC. SPC25 has a significantly higher transcriptional level in Asian patients than Caucasian patients. SPC25 promoted HCC cell proliferation in vitro and tumor growth in vivo by accelerating the cell cycle. We identified transcription factors, miRNAs, and immune cells that may interact with SPC25. Interpretation: The findings suggest that increased expression of SPC25 is associated with poor prognosis of HCC and enhances the proliferative capacity of HCC cells. SPC25 could serve as a valuable prognostic marker and a novel treatment target for HCC.

show abstract

Section: Resultsmentioning

confidence: 99%

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

Zhang

Zhou

Xie

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…Hypermethylation of gene promoters has been demonstrated as an early event in hepatocellular carcinogenesis. 25 In this study, we quantified the circulating MP16 levels using Rt-PCR in patients with HCV-related CLD for screening and early detection of HCC. These levels were significantly higher in patients with HCC as compared to patients with BLD or normal controls.…”

Section: Discussionmentioning

confidence: 99%

<p>Usefulness of Circulating Methylated p16 as a Noninvasive Molecular Biomarker for Hepatitis C-Related Hepatocellular Carcinoma with Normal Serum Alpha-Fetoprotein Levels</p>

Elsewify¹,

Hassan²,

Mekky³

et al. 2020

IJGM

View full text Add to dashboard Cite

Background: Screening of hepatocellular carcinoma (HCC) is challenged especially in patients with normal alpha-fetoprotein (AFP) levels. Aberrant p16 methylation has been implicated in HCC. Objectives and Aims: This study aimed to assess serum methylated p16 (MP16) expression levels and to evaluate MP16 diagnostic performance in HCC detection among HCVinfected Egyptian patients with normal AFP levels. Methods: MP16 levels were quantified using real-time PCR in 230 serum samples (30 healthy controls, 95 with HCV-HCC, 40 with chronic hepatitis C "CHC" and 65 with HCV cirrhosis). Diagnostic performance of MP16 for diagnosis of HCC was done using receiver operator characteristic curve analysis. Results: Serum MP16 levels were significantly higher in HCC than CHC, cirrhosis, and healthy subjects and significantly higher in HCC with normal AFP levels than those with higher AFP. ROC curves revealed promising diagnostic performance for MP16 in discriminating HCC with normal AFP levels from non-HCC cases. This predictive ability improved by combining MP16 and AFP (AUC of 0.872 with 100% sensitivity, 76.5% specificity, 79.1% positive predictive value, 100% negative predictive value, and 87.5% accuracy). Conclusion: MP16 can be a potential noninvasive molecular biomarker for HCC detection in patients with hepatic mass(es) and normal AFP levels especially in those where liver biopsy and radiological imaging cannot be done.

show abstract

“…The 1-year survival rate of PLC is only 38% [27]. CM has been employed to treat disease for a long time in Southeast Asia [28][29][30][31]. As for the aspects of limiting symptoms, reducing treatment associated side effects, inhibiting tumor growth and altering key intracellular signaling pathways, many studies have been proved that CM has advantages for patients with PLC [32][33][34].In this retrospective study, the overall survival of patients receiving CM therapy more than 6 months was prolonged.…”

Section: Discussionmentioning

confidence: 99%

Data Mining and System Pharmacology to Elucidate the Efficiency and Mechanism of Chinese Medicine in Treating Primary Liver Cancer

Zhang

Zeng

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUNDPiling studies have demonstrated that Chinese medicine (CM) is effective in treating PLC. However, underlying mechanism of CM in treating PLC remains confused. MATERIAL AND METHODThe information of 524 patients with PLC were collected and separated to CM group and Less-CM group based on the time of taking CM. Then, the prescriptions in CM group were collected to identify the corn drugs. System Pharmacology was employed to explore the mechanism of corn drugs in treating PLC.RESULTSIn univariate and multivariate analysis, taking Chinese medicines more than 6 months was an independent prognostic factor. Then, Traditional Chinese Medicine Inheritance Support System was employed to find out the core drugs that really benefit for PLC patients. Totally, 153 ingredients from 9 core drugs (HXCF) were screened out. Fifty-five genes were identified for HXCF against PLC. The pathways were found as the mechanism of HXCF to treat PLC. Docking studies suggested amount of ingredients in HXCF exerts therapeutic effects against PLC, at least in part, by modulating the function of c-JUN and IL-6.CONCLUSIONOur results verified the effectiveness of CM in treating PLC and mined the corn drugs. What’s more, our result also predicted active components and potential targets of HXCF for the application to PLC from a holistic perspective, as well as provided valuable direction for further research of HXCF and improved comprehension of PLC.

show abstract

Research Progress in Liver-Regenerating Microenvironment and DNA Methylation in Hepatocellular Carcinoma: The Role of Traditional Chinese Medicine

Cited by 11 publications

References 90 publications

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

<p>Usefulness of Circulating Methylated p16 as a Noninvasive Molecular Biomarker for Hepatitis C-Related Hepatocellular Carcinoma with Normal Serum Alpha-Fetoprotein Levels</p>

Data Mining and System Pharmacology to Elucidate the Efficiency and Mechanism of Chinese Medicine in Treating Primary Liver Cancer

Contact Info

Product

Resources

About